ResMed upgraded to Outperform as price target raised
RBC Capital upgraded ResMed to Outperform from Sector Perform and lifted its price target to $262 from $244.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
ResMed upgraded at RBC Capital Markets on Q4 positives
RBC Capital Markets on Tuesday upgraded ResMed NYSE:RMD to Outperform from Sector Perform and raised its price target to $262 from $244, citing positives in the respiratory device maker’s Q4 results for fiscal 2026.Shares of ResMed NYSE:RMD fell in early August as investors reacted to its Q4 FY26 r…